Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Successful Reversal of Tamoxifen-Associated Weight Gain and Metabolic Dysfunction with Liraglutide in a Breast Cancer Survivor: A Case Report.

Anvarbek M, Umarov D, Khalbayeva Z, Smerat A, Adi M, Ashraf A

Clinical medicine insights. Case reports27 Aug 2026

PMID42668751 (opens in a new tab)PMCIDPMC13525322 (opens in a new tab)DOI10.1177/11795476261485623 (opens in a new tab)PepBankPUB-42668751
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In one 58-year-old postmenopausal survivor of stage IIA hormone-receptor-positive breast cancer with prior tamoxifen-associated weight gain, liraglutide added while tamoxifen continued was followed by 18.5 kg weight loss over 12 months.

    In plain wordsIn one breast-cancer survivor with prior tamoxifen-related weight gain, weight fell by 18.5 kg over 12 months while liraglutide was added.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/day · 12 monthsAs given in this study (human).

    Measurements

    Weight change
    −18.5 kg
    over 12 months

    Source sentences

    Summary
    Over 12 months, she lost 18.5 kg, and her metabolic parameters, including HOMA-IR and glycated hemoglobin (HbA1c), normalized.
    4 context sentences
    Summary · context
    A 58-year-old postmenopausal woman with stage IIA, hormone-receptor positive breast cancer experienced marked weight gain after 24 months of tamoxifen therapy, despite diet and exercise.
    Summary · context
    She developed prediabetes, insulin resistance (assessed by Homeostatic Model Assessment of Insulin Resistance [HOMA-IR] 4.9), and dyslipidemia.
    Summary · context
    Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was initiated and titrated to 3.0 mg/day.
    Summary · context
    Tamoxifen therapy was continued without adverse effects.
  2. 02HumanCase report or seriesEfficacy outcome

    In one postmenopausal breast-cancer survivor with tamoxifen-associated weight gain, HOMA-IR normalized while liraglutide was added and tamoxifen continued.

    In plain wordsIn one breast-cancer survivor with tamoxifen-related weight gain, insulin-resistance testing normalized while liraglutide was added and tamoxifen continued.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedHOMA-IR
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3.0 mg/day · 12 monthsAs given in this study (human).

    Measurements

    HOMA-IR
    4.9
    baseline;post-treatment value not reported

    Source sentences

    Summary
    Over 12 months, she lost 18.5 kg, and her metabolic parameters, including HOMA-IR and glycated hemoglobin (HbA1c), normalized.
    4 context sentences
    Summary · context
    A 58-year-old postmenopausal woman with stage IIA, hormone-receptor positive breast cancer experienced marked weight gain after 24 months of tamoxifen therapy, despite diet and exercise.
    Summary · context
    She developed prediabetes, insulin resistance (assessed by Homeostatic Model Assessment of Insulin Resistance [HOMA-IR] 4.9), and dyslipidemia.
    Summary · context
    Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was initiated and titrated to 3.0 mg/day.
    Summary · context
    Tamoxifen therapy was continued without adverse effects.
  3. 03HumanCase report or seriesEfficacy outcome

    In one postmenopausal breast-cancer survivor with tamoxifen-associated weight gain, HbA1c normalized while liraglutide was added and tamoxifen continued.

    In plain wordsIn one breast-cancer survivor with tamoxifen-related weight gain, HbA1c normalized while liraglutide was added and tamoxifen continued.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedHbA1c
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3.0 mg/day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Over 12 months, she lost 18.5 kg, and her metabolic parameters, including HOMA-IR and glycated hemoglobin (HbA1c), normalized.
    4 context sentences
    Summary · context
    A 58-year-old postmenopausal woman with stage IIA, hormone-receptor positive breast cancer experienced marked weight gain after 24 months of tamoxifen therapy, despite diet and exercise.
    Summary · context
    She developed prediabetes, insulin resistance (assessed by Homeostatic Model Assessment of Insulin Resistance [HOMA-IR] 4.9), and dyslipidemia.
    Summary · context
    Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was initiated and titrated to 3.0 mg/day.
    Summary · context
    Tamoxifen therapy was continued without adverse effects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.